APA (7th ed.) Citation

D, B., H, L., G, A., C, P., A, B., G, F., . . . AM, D. (2010). A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: A Hellenic Cooperative Oncology Group study. BMC medicine, 8, 3. https://doi.org/10.1186/1741-7015-8-3

Chicago Style (17th ed.) Citation

D, Bafaloukos, et al. "A Randomized Phase II Study of Carboplatin Plus Pegylated Liposomal Doxorubicin Versus Carboplatin Plus Paclitaxel in Platinum Sensitive Ovarian Cancer Patients: A Hellenic Cooperative Oncology Group Study." BMC Medicine 8 (2010): 3. https://doi.org/10.1186/1741-7015-8-3.

MLA (9th ed.) Citation

D, Bafaloukos, et al. "A Randomized Phase II Study of Carboplatin Plus Pegylated Liposomal Doxorubicin Versus Carboplatin Plus Paclitaxel in Platinum Sensitive Ovarian Cancer Patients: A Hellenic Cooperative Oncology Group Study." BMC Medicine, vol. 8, 2010, p. 3, https://doi.org/10.1186/1741-7015-8-3.